CAT-09-833 / Catalent - LARVOL DELTA

DB-1326, a novel dual-payload TA-MUC1-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model (AACR 2026) - "Several antibody-drug conjugates (ADCs) targeting TA-MUC1 are in development in clinical and preclinical stage, such as DS-3939a, CAT-09-833... DB-1326 is a novel dual-payload ADC with a TA-MUC1 antibody. It displayed high tumor cell selectivity and superior anti-tumor effects in preclinical studies. These findings support the potential of DB-1326 as a promising advanced therapeutic candidate for tumors."

ADC • Preclinical • Oncology • MUC1

Catalent’s SMARTag ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego (Businesswire) - "The company announced preclinical efficacy and tolerability data demonstrating the potential of CAT-09-833, a SMARTag ADC targeting MUC1, for the treatment of platinum-resistant ovarian cancer. The company also introduced SMARTag Enhanced Conjugates, a new class of ADCs that combines different payload types to benefit more patients by amplifying efficacy without compromising safety."

Platinum resistant • Preclinical • Ovarian Cancer